Cargando…

Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter

Background and Aims: Inflammatory bowel diseases (IBD) are frequently associated with extraintestinal manifestations, hepatic injury being of concern in these patients. Current literature reports an increased prevalence of liver steatosis and fibrosis in subjects with IBD and the pathophysiology is...

Descripción completa

Detalles Bibliográficos
Autores principales: Trifan, Anca, Stafie, Remus, Rotaru, Adrian, Stratina, Ermina, Zenovia, Sebastian, Nastasa, Robert, Huiban, Laura, Cuciureanu, Tudor, Muzica, Cristina, Chiriac, Stefan, Girleanu, Irina, Singeap, Ana-Maria, Sfarti, Catalin, Cojocariu, Camelia, Petrea, Oana, Stanciu, Carol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573563/
https://www.ncbi.nlm.nih.gov/pubmed/36233826
http://dx.doi.org/10.3390/jcm11195959
_version_ 1784810903735107584
author Trifan, Anca
Stafie, Remus
Rotaru, Adrian
Stratina, Ermina
Zenovia, Sebastian
Nastasa, Robert
Huiban, Laura
Cuciureanu, Tudor
Muzica, Cristina
Chiriac, Stefan
Girleanu, Irina
Singeap, Ana-Maria
Sfarti, Catalin
Cojocariu, Camelia
Petrea, Oana
Stanciu, Carol
author_facet Trifan, Anca
Stafie, Remus
Rotaru, Adrian
Stratina, Ermina
Zenovia, Sebastian
Nastasa, Robert
Huiban, Laura
Cuciureanu, Tudor
Muzica, Cristina
Chiriac, Stefan
Girleanu, Irina
Singeap, Ana-Maria
Sfarti, Catalin
Cojocariu, Camelia
Petrea, Oana
Stanciu, Carol
author_sort Trifan, Anca
collection PubMed
description Background and Aims: Inflammatory bowel diseases (IBD) are frequently associated with extraintestinal manifestations, hepatic injury being of concern in these patients. Current literature reports an increased prevalence of liver steatosis and fibrosis in subjects with IBD and the pathophysiology is yet to be completely understood. The aim of this study was to assess the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with IBD, as well as to determine the factors that connect these two disorders. Methods: From September 2021 to June 2022, 82 consecutive IBD patients were enrolled from a tertiary care center hospital in Iasi. Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter (CAP) was used to assess the presence of NAFLD, with a cut-off score for CAP of 248 dB/m. Significant liver fibrosis was considered at a cut-off for liver stiffness measurements (LSM) of 7.2 kPa. Results: In total, 82 IBD patients (54.8% men, mean age of 49 ± 13 years) were included, 38 (46.3%) of them being diagnosed with NAFLD, with a mean CAP score of 286 ± 35.4 vs. 203 ± 29.7 in patients with IBD only. Age (β = 0.357, p = 0.021), body mass index (BMI) (β = 0.185, p = 0.048), disease duration (β = 0.297, p = 0.041), C—reactive protein (β = 0.321, p = 0.013), fasting plasma glucose (β = 0.269, p = 0.038), and triglycerides (β = 0.273, p = 0.023) were strongly associated with the presence of liver steatosis. The multivariate analysis showed that older age, BMI, and disease duration were strongly associated with significant liver fibrosis in our group. Conclusions: NAFLD is a multifaced pathology with growing prevalence among IBD patients. Additional studies are needed to completely understand this problem and to create a solid evidence-based framework for more effective preventative and intervention strategies.
format Online
Article
Text
id pubmed-9573563
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95735632022-10-17 Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter Trifan, Anca Stafie, Remus Rotaru, Adrian Stratina, Ermina Zenovia, Sebastian Nastasa, Robert Huiban, Laura Cuciureanu, Tudor Muzica, Cristina Chiriac, Stefan Girleanu, Irina Singeap, Ana-Maria Sfarti, Catalin Cojocariu, Camelia Petrea, Oana Stanciu, Carol J Clin Med Article Background and Aims: Inflammatory bowel diseases (IBD) are frequently associated with extraintestinal manifestations, hepatic injury being of concern in these patients. Current literature reports an increased prevalence of liver steatosis and fibrosis in subjects with IBD and the pathophysiology is yet to be completely understood. The aim of this study was to assess the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with IBD, as well as to determine the factors that connect these two disorders. Methods: From September 2021 to June 2022, 82 consecutive IBD patients were enrolled from a tertiary care center hospital in Iasi. Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter (CAP) was used to assess the presence of NAFLD, with a cut-off score for CAP of 248 dB/m. Significant liver fibrosis was considered at a cut-off for liver stiffness measurements (LSM) of 7.2 kPa. Results: In total, 82 IBD patients (54.8% men, mean age of 49 ± 13 years) were included, 38 (46.3%) of them being diagnosed with NAFLD, with a mean CAP score of 286 ± 35.4 vs. 203 ± 29.7 in patients with IBD only. Age (β = 0.357, p = 0.021), body mass index (BMI) (β = 0.185, p = 0.048), disease duration (β = 0.297, p = 0.041), C—reactive protein (β = 0.321, p = 0.013), fasting plasma glucose (β = 0.269, p = 0.038), and triglycerides (β = 0.273, p = 0.023) were strongly associated with the presence of liver steatosis. The multivariate analysis showed that older age, BMI, and disease duration were strongly associated with significant liver fibrosis in our group. Conclusions: NAFLD is a multifaced pathology with growing prevalence among IBD patients. Additional studies are needed to completely understand this problem and to create a solid evidence-based framework for more effective preventative and intervention strategies. MDPI 2022-10-09 /pmc/articles/PMC9573563/ /pubmed/36233826 http://dx.doi.org/10.3390/jcm11195959 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Trifan, Anca
Stafie, Remus
Rotaru, Adrian
Stratina, Ermina
Zenovia, Sebastian
Nastasa, Robert
Huiban, Laura
Cuciureanu, Tudor
Muzica, Cristina
Chiriac, Stefan
Girleanu, Irina
Singeap, Ana-Maria
Sfarti, Catalin
Cojocariu, Camelia
Petrea, Oana
Stanciu, Carol
Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter
title Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter
title_full Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter
title_fullStr Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter
title_full_unstemmed Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter
title_short Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter
title_sort screening for liver steatosis and fibrosis in patients with inflammatory bowel disease using vibration controlled transient elastography with controlled attenuation parameter
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573563/
https://www.ncbi.nlm.nih.gov/pubmed/36233826
http://dx.doi.org/10.3390/jcm11195959
work_keys_str_mv AT trifananca screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter
AT stafieremus screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter
AT rotaruadrian screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter
AT stratinaermina screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter
AT zenoviasebastian screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter
AT nastasarobert screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter
AT huibanlaura screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter
AT cuciureanutudor screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter
AT muzicacristina screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter
AT chiriacstefan screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter
AT girleanuirina screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter
AT singeapanamaria screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter
AT sfarticatalin screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter
AT cojocariucamelia screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter
AT petreaoana screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter
AT stanciucarol screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter